Glaucoma News and Research

Latest Glaucoma News and Research

IUPUI's Jason Meyer awarded $1.8 million NIH grant to explore how glaucoma develops in stem cells

Jason Meyer, Ph.D., assistant professor of biology in the School of Science at Indiana University-Purdue University Indianapolis, has received a National Institutes of Health grant to study how glaucoma develops in stem cells created from skin cells genetically predisposed to the disease.

20 Feb 2015

Scientists identify promising new therapeutic target for prostate cancer

Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma.

20 Feb 2015

Understanding the pattern of cellular changes that lead to retinal ganglion cell death in glaucoma

Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease.

12 Feb 2015

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma.

12 Feb 2015

New study shows that 25% of homeless people in Toronto have vision problems

Twenty-five per cent of homeless people surveyed in Toronto had vision problems up to and including blindness, four times higher than the rate of the overall population in North America, a new study by St. Michael's Hospital has found.

6 Feb 2015

Study: Lower-income students in China have better vision compared to middle-class counterparts

In one of the largest population-based studies ever conducted on nearsightedness in children, researchers have discovered that lower-income students in China have better vision than their middle-class counterparts. Data show that nearsightedness, also called myopia, is twice as prevalent in the middle-income province of Shaanxi compared to the poorer neighboring province of Gansu.

5 Feb 2015

IRIDEX Cyclo G6 Laser System receives FDA clearance for treatment of glaucoma

IRIDEX Corporation today announced that it has received clearance from the U.S. Food and Drug Administration to market its first laser system designed solely for use in treating glaucoma and its symptoms. Specifically, the Company was granted 510(k) clearance for the IRIDEX Cyclo G6 Laser System (with delivery devices).

2 Feb 2015

Abbott's new TECNIS Multifocal IOLs now available in the U.S. for people with cataracts

Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States. The new TECNIS Multifocal IOLs, developed by Abbott, provide people with cataracts options to have a full range of near, intermediate and distance vision, while customizing their treatment based on their personal vision needs and lifestyle.

30 Jan 2015

Scientists identify new molecular pathway that controls axonal degeneration following injury

Axons connect neurons with each other to form the neural networks that underpin the vital functions of perception, motility, cognition, and memory. In many neurodegenerative disorders, from traumatic injury or toxic damage to diseases such as Alzheimer's or Parkinson's disease, axonal degeneration represents an essential pathological feature.

23 Jan 2015

New discovery may help doctors develop better treatments for brain, spinal cord injuries

In a discovery that could dramatically affect the treatment of brain and spinal cord injuries, researchers have identified a previously unknown, beneficial immune response that occurs after injury to the central nervous system.

23 Jan 2015

UAB Research Probes Molecular Basis Of Rare Genetic Disorder

An international group co-led by University of Alabama at Birmingham researcher Mary MacDougall, Ph.D., has unraveled the molecular basis for the rare, inherited genetic disorder, Singleton-Merten Syndrome (SMS). Individuals with SMS develop extreme, life-threatening calcification of the aorta and heart valves, early-onset periodontitis and root resorption of the teeth, decreases in bone density, and loss of bone tissue at the tips of fingers and toes.

23 Jan 2015

BioLight invests in newly-formed ophthalmic company

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.

12 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to Oraya over a period of up to two years for the implementation of Oraya’s growth strategy, and in turn receive rights in the company reaching up to a majority stake after two years.

8 Jan 2015

Glaucoma Awareness Month: Mount Sinai ophthalmologists offer tips for glaucoma prevention

Glaucoma, a degenerative eye disease that causes damage to the optic nerve, is the second leading cause of blindness in the world, according to the World Health Organization. To observe Glaucoma Awareness Month, ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai and the Mount Sinai Health System are offering tips for prevention and early detection of the condition.

7 Jan 2015

Chronic hypertension increases glaucoma risk

A new study published in Investigative Ophthalmology & Visual Science has found that chronic (long term) hypertension increases a person's susceptibility to glaucoma. These results suggest that doctors should consider a patient's blood pressure levels in managing the potentially blinding eye disorder.

6 Jan 2015

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

Prostaglandin analogue eye drops, the most commonly prescribed treatment for glaucoma, can greatly reduce risk of vision loss in people with open angle glaucoma (OAG), one of the leading causes of blindness, according to the first placebo-controlled trial to assess their vision-preserving effect published in The Lancet.

22 Dec 2014

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

IRIDEX Corporation (Nasdaq: IRIX) announced today that its China distributor has been awarded a competitive tender for more than $620,000 in ophthalmology laser equipment to fulfill a government program designed to provide advanced ophthalmology solutions to patients across vast areas of China's rural regions.

2 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

Understanding the genetic basis of glaucoma

Scientists from the University of Liverpool have sequenced the mitochondrial genome in glaucoma patients to help further understanding into the genetic basis for the disease.

16 Nov 2014

Glaucoma News and Research

Latest Glaucoma News and Research

IUPUI's Jason Meyer awarded $1.8 million NIH grant to explore how glaucoma develops in stem cells

Scientists identify promising new therapeutic target for prostate cancer

Understanding the pattern of cellular changes that lead to retinal ganglion cell death in glaucoma

OIB Program helps older Californians with blindness to live and work independently

New study shows that 25% of homeless people in Toronto have vision problems

Study: Lower-income students in China have better vision compared to middle-class counterparts

IRIDEX Cyclo G6 Laser System receives FDA clearance for treatment of glaucoma

Abbott's new TECNIS Multifocal IOLs now available in the U.S. for people with cataracts

Scientists identify new molecular pathway that controls axonal degeneration following injury

New discovery may help doctors develop better treatments for brain, spinal cord injuries

UAB Research Probes Molecular Basis Of Rare Genetic Disorder

BioLight invests in newly-formed ophthalmic company

FDA approves RYTARY for Parkinson's disease treatment

Carl Zeiss Meditec to invest in Oraya Therapy for treatment of wet AMD

Glaucoma Awareness Month: Mount Sinai ophthalmologists offer tips for glaucoma prevention

Chronic hypertension increases glaucoma risk

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

Eylea receives Health Canada approval for treatment of CRVO and DME

Understanding the genetic basis of glaucoma

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Glaucoma News and Research

Latest Glaucoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in